ArticleAnnals of the rheumatic diseases2020
Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals.Aging cell · 2026Article
- Frailty status and mortality among patients with cardiometabolic diseases in an international multi-cohort study.iScience · 2026Article
- Comprehensive Research Progress on Glucosamine: A Review.Applied biochemistry and biotechnology · 2026Review
- Relationship between habitual glucosamine use and risk of incident idiopathic pulmonary fibrosis with the modification effect of genetic susceptibility: a prospective cohort study.European journal of nutrition · 2026Article
- Article
- Glucosamine Use and Its Association with Colorectal Cancer and Mortality: A Systematic Review and Meta-Analysis.Journal of Cancer · 2026Article
- Effects of D-Glucosamine on the Growth of Human Gut-Dominant MicrobiotaJournal of applied glycoscience · 2026Article
- Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges.ACS pharmacology & translational science · 2025Review
- Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study.BMJ open · 2025Article
- Aspirin-Inspired 6-O-Carboxymethyl-N-Acetylglucosamine: A potent antitumor agent with enhanced efficacy.Apoptosis : an international journal on programmed cell death · 2025Article
- Regular glucosamine supplementation and risk of age-related chronic diseases: evidence from a propensity score-matched cohort study.Aging clinical and experimental research · 2025Article
- Joint Physical-Psychosocial Frailty and Risks of All-Cause and Cause-Specific Premature Mortality.Journal of general internal medicine · 2025Article
- Calorie restriction mimetics against aging and inflammation.Biogerontology · 2025Review
- Degree of joint risk factor control and premature mortality in hypertensive participants.Precision clinical medicine · 2025Article
- Glucose transporter 2‑transported glucosamine inhibits glycolysis in cancer cell lines through competition with glucose for hexokinase II.Oncology reports · 2025Article
- Dietary glucosamine supplement use and lower surgery risk in individuals with inflammatory bowel disease: a prospective Cohort Study.European journal of nutrition · 2025Article
- Association of Accelerometer-Derived Physical Activity Pattern With the Risks of All-Cause, Cardiovascular Disease, and Cancer Death.Journal of the American Heart Association · 2025Article
- Accelerometer-derived physical activity patterns and incident type 2 diabetes: a prospective cohort study.The international journal of behavioral nutrition and physical activity · 2025Article
- Plasma Glutaminyl-Peptide Cyclotransferase Mediates Glucosamine-Metabolism-Driven Protection Against Hypertension: A Mendelian Randomization Study.International journal of molecular sciences · 2024Article
- Association between fish oil and glucosamine use and mortality in patients diagnosed with cancer: the role of the Life Essential 8 score and cancer prognosis.Nutrition journal · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors.
Funding
Abstract
objectivesTo evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort.
methodsThis population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables.
resultsAt baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080).
conclusionsRegular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.